Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postauthorization Safety Surveillance of Xyntha in Hemophilia A
NCT00765726Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Feb 2009
- Primary completion
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 4 trial of moroctocog alfa in hemophilia A, sponsored by Pfizer. Started Feb 2009; status: terminated.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00765726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00765726.